Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine Reduction/Elimination with Rapamune in Kidney Transplant
NCT00257387Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2004
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of sirolimus in kidney transplant rejection (2 arms), sponsored by Pfizer. Primary endpoint: Incidence and severity of acute rejection at 6 months. Started Jun 2004; status: completed.
02
Drugs
sirolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00257387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257387.